BridgeBio Pharma Inc

NASDAQ:BBIO   12:07:06 PM EDT
10.47
+0.54 (+5.44%)
Products, Regulatory

Bridgebio Pharma announces dosing of first patient in Phase 1 trial of BBP-671, a potential best-in-class treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)

Published: 08/18/2022 11:37 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Announces Dosing of First Patient in Phase 1 Trial of Bbp-671, a Potential Best-in-class Treatment for Propionic Acidemia (pa) and Methylmalonic Acidemia (mma).
Bridgebio Pharma Inc - Initial Data Readout for Patients With Pa and Mma Expected in First Half of 2023.
Bridgebio - Expects to Launch Pivotal Phase 2/3 Clinical Study of Bbp-671 in Pantothenate Kinase-associated Neurodegeneration in 2023.